Sutro Biopharma (STRO) Payables (2017 - 2026)
Sutro Biopharma (STRO) posted Payables of $7.6 million for Q4 2025, up 7.55% sequentially from $7.0 million in Q3 2025, and down 27.78% YoY from $10.5 million in Q4 2024.
Sutro Biopharma (STRO) Payables (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Payables for 9 years, with the latest figure at $7.6 million in Q4 2025.
- Quarterly Payables fell 27.78% year-over-year to $7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.6 million (down 27.78% YoY) and the FY2025 annual result came in at $7.6 million, down 27.78% from the prior year.
- Payables advanced to $7.6 million in Q4 2025 per STRO's latest filing, from $7.0 million in the prior quarter.
- Over five years, Payables peaked at $12.6 million in Q2 2022 and troughed at $3.9 million in Q2 2023.
- A 5-year average of $7.6 million and a median of $7.3 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2021 and 2023: Payables soared 129.0% in 2021, then tumbled 69.32% in 2023.
- Over 5 years, Payables stood at $6.0 million in 2021, then slipped by 20.17% to $4.8 million in 2022, then soared by 96.79% to $9.4 million in 2023, then gained by 10.96% to $10.5 million in 2024, then declined by 27.78% to $7.6 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $7.6 million, $7.0 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.36 Mn |
| Dec 31, 2025 | 7.57 Mn |
| Sep 30, 2025 | 7.03 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Mar 31, 2025 | 8.18 Mn |
| Dec 31, 2024 | 10.48 Mn |
| Sep 30, 2024 | 6.22 Mn |
| Jun 30, 2024 | 6.09 Mn |
| Mar 31, 2024 | 7.51 Mn |
| Dec 31, 2023 | 9.44 Mn |
| Sep 30, 2023 | 5.53 Mn |
| Jun 30, 2023 | 3.86 Mn |
| Mar 31, 2023 | 5.06 Mn |
| Dec 31, 2022 | 4.80 Mn |
| Sep 30, 2022 | 12.44 Mn |
| Jun 30, 2022 | 12.57 Mn |
| Mar 31, 2022 | 10.71 Mn |
| Dec 31, 2021 | 6.01 Mn |
| Sep 30, 2021 | 11.17 Mn |
| Jun 30, 2021 | 7.64 Mn |